MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Beam Therapeutics Long Term Debt Current 2011-2026 | BEAM
Annual Long Term Debt Current Beam Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.5 M | 12.8 M | 10.4 M | 7.54 M | 4.22 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.5 M | 4.22 M | 9.68 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M |  Canada |
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
1.18 M | $ 2.8 | -3.69 % | $ 158 M |  China |
 |
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | USA |
 |
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
1.8 M | $ 80.89 | -1.35 % | $ 1.56 B | USA |
 |
Amgen
AMGN
|
107 M | $ 341.41 | -0.45 % | $ 183 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
Aytu BioScience
AYTU
|
137 K | $ 2.68 | 3.88 % | $ 16.8 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.23 | -1.01 % | $ 7.77 B |  Australia |
 |
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | USA |
 |
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | USA |
 |
Aptose Biosciences
APTO
|
428 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Brickell Biotech
BBI
|
49 K | - | -5.38 % | $ 6.06 M | USA |
 |
Biogen
BIIB
|
86.4 M | $ 177.21 | 0.61 % | $ 25.8 B | USA |
 |
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | USA |
 |
Ascendis Pharma A/S
ASND
|
14.2 M | $ 224.26 | 0.14 % | $ 5 B |  Danmark |
 |
Athira Pharma
ATHA
|
414 K | - | - | $ 269 M | USA |
 |
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioNTech SE
BNTX
|
39.5 M | $ 115.04 | -1.49 % | $ 27.2 B | Germany |
 |
Arrowhead Pharmaceuticals
ARWR
|
7.29 M | $ 68.78 | -0.5 % | $ 9.2 B | USA |
 |
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
428 K | - | -10.17 % | $ 12.2 K | USA |
 |
CASI Pharmaceuticals
CASI
|
1.06 M | $ 1.01 | 1.6 % | $ 137 M | USA |
 |
Catalyst Biosciences
CBIO
|
210 K | $ 9.79 | -3.55 % | $ 644 M | USA |
 |
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
11 M | - | -9.72 % | $ 5.89 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
5.38 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Berkeley Lights
BLI
|
3.29 M | - | -7.31 % | $ 87 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 4.0 | -3.61 % | $ 8.7 B |  Israel |
 |
Amneal Pharmaceuticals
AMRX
|
224 M | $ 14.0 | -0.78 % | $ 4.33 B | USA |
 |
AIkido Pharma
AIKI
|
410 K | - | 1.93 % | $ 17.4 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
203 K | - | -74.18 % | $ 955 K | USA |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | USA |
 |
Cerus Corporation
CERS
|
2.28 M | $ 2.28 | -1.94 % | $ 421 M | USA |
 |
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
10.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | USA |
 |
Baudax Bio
BXRX
|
5.6 M | - | 0.59 % | $ 63 K | USA |